[A22-46] Dupilumab (severe asthma with type 2 inflammation) - Benefit assessment according to §35a Social Code Book V

Last updated 15.07.2022

Project no.:
A22-46

Commission:
Commission awarded on 19.04.2022 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Children's and adolescents' health

Indication:

Children between 6 and 11 years of age with severe asthma with type 2 inflammation which is not properly controlled despite moderate-to-high-dose inhaled corticosteroids (ICS) plus one further drug as maintenance treatment.

Result of dossier assessment:

Added benefit not proven

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

informedhealth.org logo Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form